<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Triclabendazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Triclabendazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Triclabendazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="120435" href="/d/html/120435.html" rel="external">see "Triclabendazole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="120674" href="/d/html/120674.html" rel="external">see "Triclabendazole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53144129"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Egaten</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52759217"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anthelmintic</li></ul></div>
<div class="block doa drugH1Div" id="F52854265"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2421c6ae-47fa-4c4d-b513-3b426b166737">Fascioliasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fascioliasis:</b> Oral: 10 mg/kg every 12 hours for 2 doses (the 250 mg tablets are scored and divisible into two equal halves of 125 mg; if the dosage cannot be adjusted exactly, round the dose upwards).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F52854267"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F52854268"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F52854266"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52797382"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="120674" href="/d/html/120674.html" rel="external">see "Triclabendazole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2421c6ae-47fa-4c4d-b513-3b426b166737">Fascioliasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fascioliasis:</b> Children ≥6 years and Adolescents: Oral: 10 mg/kg/dose every 12 hours for 2 doses. <b>Note:</b> Round dose up to the nearest half (125 mg) or whole tablet (250 mg).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52778869"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F52778870"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block adr drugH1Div" id="F52799698"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (25%), urticaria (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (93%), decreased appetite (18%), nausea (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (7%), vomiting (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (7%), increased serum aspartate aminotransferase (5%), increased serum alkaline phosphatase (4%), increased serum alanine aminotransferase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Increased liver enzymes</p></div>
<div class="block coi drugH1Div" id="F52759219"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to triclabendazole, other benzimidazole derivatives, or to any component of the formulation</p></div>
<div class="block war drugH1Div" id="F52854253"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic toxicity: Transient increases in liver enzymes and total bilirubin have been reported in patients receiving triclabendazole.</p>
<p style="text-indent:-2em;margin-left:4em;">• QTc prolongation: QTc interval prolongation may occur. Monitor ECG in patients with a history of known or suspected QTc prolongation; electrolyte disturbances (eg, hypokalemia); risk factors for increased exposure to triclabendazole and/or metabolites (eg, hepatic impairment, CYP1A2 inhibitors); or when used with concomitant QTc-prolonging drugs.</p></div>
<div class="block foc drugH1Div" id="F53144130"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Egaten: 250 mg [scored; contains corn starch]</p></div>
<div class="block geq drugH1Div" id="F53144128"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53184084"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Egaten Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F54235646"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Egaten is only available via the Egaten Free Goods Program. Distribution is provided by AllCare Plus Pharmacy. Additional information may be obtained by contacting AllCare Plus Pharmacy at (888) 774-7327.</p></div>
<div class="block adm drugH1Div" id="F52854269"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food. Tablets may be swallowed whole or divided in half and taken with water or crushed and administered with applesauce. The crushed tablet mixed with applesauce is stable for up to 4 hours.</p></div>
<div class="block admp drugH1Div" id="F52778882"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food and water; tablet may be swallowed whole, divided in half, or crushed and sprinkled over a small amount of applesauce; administer within 4 hours; round dose up to the nearest whole or half tablet</p></div>
<div class="block use drugH1Div" id="F52759218"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Fascioliasis:</b> Treatment of fascioliasis in patients ≥6 years of age</p></div>
<div class="block cyt drugH1Div" id="F52791736"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F52791733"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F52854255"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases triclabendazole and sulfoxide metabolite AUC and C<sub>max </sub>2 and 3-fold, respectively. Management: Take with food.</p></div>
<div class="block pri drugH1Div" id="F52854251"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of triclabendazole in pregnancy is limited (Alatoom 2008).</p></div>
<div class="block brc drugH1Div" id="F52854252"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if triclabendazole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F52854271"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor ECG in patients with a history of known or suspected QT prolongation, electrolyte disturbances (eg, hypokalemia), risk factors for increased exposure to triclabendazole and/or metabolites (eg, hepatic impairment, CYP1A2 inhibitors), or when used with concomitant QTc-prolonging drugs.</p></div>
<div class="block pha drugH1Div" id="F52854257"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Triclabendazole is an anthelmintic against <i>Fasciola </i>species. In vitro data suggest that triclabendazole and its active metabolites are absorbed by the tegument of the immature and mature worms, leading to a decrease of the resting membrane potential, inhibition of motility, disruption of the surface as well as ultrastructure that include inhibition of spermatogenesis and vitelline cells.</p></div>
<div class="block phk drugH1Div" id="F52854258"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Increased absorption with food (Lecaillon 1998)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Triclabendazole: 96.7%; Sulfoxide metabolite: 98.4%; Sulfone metabolite: 98.8% in human plasma</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily metabolized by CYP1A2 (~64%) into its active sulfoxide metabolite and to a lesser extent by CYP2C9, CYP2C19, CYP2D6, CYP3A, and FMO. Sulfoxide metabolite is further metabolized primarily by CYP2C9 to the active sulfone metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Triclabendazole: 8 hours; Sulfoxide metabolite: 14 hours; Sulfone metabolite: 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: T<sub>max</sub> 3.0 ± 0.4 hours (El-Tantawy 2007)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18669773">
<a name="18669773"></a>Alatoom A, Sheffield J, Gander RM, Shaw J, Cavuoti D. Fascioliasis in pregnancy. <i>Obstet Gynecol</i>. 2008;112(2 Pt 2):483-485. doi:10.1097/AOG.0b013e31817c4ea7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triclabendazole-drug-information/abstract-text/18669773/pubmed" id="18669773" target="_blank">18669773</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17265093">
<a name="17265093"></a>El-Tantawy WH, Salem HF, Safwat NASM. Effect of <i>Fascioliasis</i> on the pharmacokinetic parameters of triclabendazole in human subjects. <i>Pharm World Sci.</i> 2007;29:190-198. doi:10.1007/s11096-006-9069-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triclabendazole-drug-information/abstract-text/17265093/pubmed" id="17265093" target="_blank">17265093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9663817">
<a name="9663817"></a>Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. <i>Br J Clin Pharmacol.</i> 1998;45(6):601-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triclabendazole-drug-information/abstract-text/9663817/pubmed" id="9663817" target="_blank">9663817</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120383 Version 39.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
